Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin/Nyloxin Extra Strength, an over-the-counter (OTC) pain reliever; Pet Pain-Away, a homeopathic, non"narcotic, non"addictive, over"the"counter pain reliever to treat moderate to severe chronic pain in companion animals; Equine Pain-Away, an OTC topical pain reliever to relieve pain in horses; and Luxury Feet, an OTC pain reliever for foot pain from high heels and stilettos. It is also involved in developing RPI-78M to treat neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, and general anti -viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Boca Raton, Florida.